The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
Title | The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Makras, P., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Anastasilakis A. D. |
Journal | Bone |
Volume | 138 |
Pagination | 115478 |
Date Published | 2020 Sep |
ISSN | 1873-2763 |
Abstract | INTRODUCTION: In women with postmenopausal osteoporosis denosumab discontinuation is associated with rapid bone loss that could be potentially prevented by a single zoledronate infusion for two years. The longer-term effects, however, of zoledronate treatment are unknown. We aimed to study the effect of a single zoledronate infusion during the third year following denosumab discontinuation, in initially treatment-naive postmenopausal women who became osteopenic after 2.4 ± 0.2 years of denosumab therapy. |
DOI | 10.1016/j.bone.2020.115478 |
Alternate Journal | Bone |
PubMed ID | 32534221 |